Risk factors

Q32 Bio (QTTB) risk factors

Item 1A of every Q32 Bio Inc. 10-K on file, and what changed from one year to the next.

Open QTTB in Gloomberb →
  • FY2025 10-K risk factors

    79 risks, 7 new, 11 dropped, 14 reworded since the prior year. Q32 Bio added new risks covering Nasdaq minimum equity compliance, AI healthcare regulations, and stock option repricing consequences. The company updated financial figures, including NOLs of $423.3 million and $2.4 million in state R&D tax credits.

    Filed Mar 10, 2026
  • FY2024 10-K risk factors

    83 risks. Clinical-stage biotech focused on bempikibart after discontinuing ADX-097 in February 2025. Highly reliant on raising capital, patent protection, and FDA regulatory approvals to survive.

    Filed Mar 11, 2025